<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740294</url>
  </required_header>
  <id_info>
    <org_study_id>20.1171</org_study_id>
    <nct_id>NCT04740294</nct_id>
  </id_info>
  <brief_title>Efficacy of Magnesium Sulfate Bolus in Pediatric Patients With Bronchiolitis</brief_title>
  <official_title>Efficacy of Magnesium Sulfate Bolus in Pediatric Patients With Bronchiolitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to more rigorously evaluate the response to a single bolus of&#xD;
      magnesium sulfate in a population of patients with moderate to severe bronchiolitis. The&#xD;
      primary outcome will be to evaluate the effect of this therapy on clinical respiratory&#xD;
      status. Secondary outcomes of interest will include the incidence of adverse effects and&#xD;
      safety profile of magnesium bolus use in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized placebo-controlled pilot study is designed to evaluate the above referenced&#xD;
      outcomes. Study drug initiation will occur in the local pediatric intensive care unit in&#xD;
      patients with a clinical diagnosis of bronchiolitis and whose parent/LAR consents for their&#xD;
      participation. Our goal is to enroll and evaluate a total of 40 patients.&#xD;
&#xD;
      Upon obtaining informed consent, the participant will receive an enrollment history and&#xD;
      physical to include: baseline Modified Pulmonary Index Score (MPIS), blood pressure, vital&#xD;
      signs, and epidemiologic data. The participant will then receive either a bolus of 50mg/kg&#xD;
      Magnesium Sulfate (MgSO4) or normal saline as placebo medication over twenty minutes. Vital&#xD;
      signs and MPIS will be monitored according to the study schedule, for a total of six hours.&#xD;
      During the period of monitoring subjects will not receive additional bronchodilators unless&#xD;
      otherwise deemed clinically necessary by the subject's attending physician. If administered,&#xD;
      these will be recorded by investigative team.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized placebo-controlled pilot study with 1:1 randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinding will be done in the pharmacy using a pre-developed randomization table. Study medication, whether MgSO4 or placebo, will be prepared by a study pharmacist and sent to the nursing/clinical staff for administration labelled as &quot;study drug&quot;. Unblinding, if clinically indicated, can be provided to the treatment team but it is not anticipated that this will be required.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of this therapy on clinical respiratory status</measure>
    <time_frame>6 hours post bolus of medication versus placebo</time_frame>
    <description>MPIS will be used to follow respiratory status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify the incidence of adverse effects and safety profile of magnesium sulfate</measure>
    <time_frame>6 hours post bolus of medication versus placebo</time_frame>
    <description>Patients will be followed for any potential adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bronchiolitis, Viral</condition>
  <arm_group>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will receive a bolus of 50mg/kg MgSO4 over twenty minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patient will receive a bolus of Normal Saline over twenty minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>Randomized to receive either magnesium sulfate or normal saline placebo.</description>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants under 12 months of age&#xD;
&#xD;
          -  Admitted to the pediatric intensive care unit&#xD;
&#xD;
          -  Moderate/severe bronchiolitis using MPIS&#xD;
&#xD;
          -  Less than 24 hours of admission to the PICU&#xD;
&#xD;
          -  Parent/LAR consents for infant to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with the following conditions are ineligible: chronic lung disease,&#xD;
             unrepaired congenital heart disease, and cyanotic heart disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Berkenbosch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John W Berkenbosch, MD</last_name>
    <phone>502-852-3720</phone>
    <email>john.berkenbosch@louisville.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janice Sullivan, MD</last_name>
    <phone>502-629-5283</phone>
    <email>sully@louisville.edu</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>John W Berkenbosch</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis, Viral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The information will not be shared outside of the University except as de-identified data for presentation of results virtually or in print.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

